Clinical Trials | May 08, 2026
Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial
NEJM study shows strong protection across strains
NEJM study shows strong protection across strains
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The decision marks a pivotal moment for the Massachusetts-based biotech giant
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
Subscribe To Our Newsletter & Stay Updated
